Rudd R - Search Results

1

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA. Blayney JK, et al. Among authors: rudd r. Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15. Eur J Cancer. 2012. PMID: 22704893

2

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Fennell DA, et al. Among authors: rudd r. J Clin Oncol. 2005 Jan 1;23(1):184-9. doi: 10.1200/JCO.2005.07.050. J Clin Oncol. 2005. PMID: 15625372

3

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.

Fennell DA, Rudd RM. Fennell DA, et al. Lancet Oncol. 2004 Jun;5(6):354-62. doi: 10.1016/S1470-2045(04)01492-5. Lancet Oncol. 2004. PMID: 15172356 Review.

4

Prognostic factors in mesothelioma.

Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Steele JP, et al. Lung Cancer. 2005 Jul;49 Suppl 1:S49-52. doi: 10.1016/j.lungcan.2005.03.009. Lung Cancer. 2005. PMID: 15894403

5

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Fennell DA, et al. Cancer. 2007 Jan 1;109(1):93-9. doi: 10.1002/cncr.22366. Cancer. 2007. PMID: 17146783 Free article.

6

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. Stebbing J, et al. Lung Cancer. 2009 Jan;63(1):94-7. doi: 10.1016/j.lungcan.2008.04.001. Epub 2008 May 16. Lung Cancer. 2009. PMID: 18486273

7

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Fennell DA, et al. Lung Cancer. 2005 Feb;47(2):277-81. doi: 10.1016/j.lungcan.2004.08.005. Lung Cancer. 2005. PMID: 15639727 Clinical Trial.

8

Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).

Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Klabatsa A, et al. Among authors: rudd rm. Lung Cancer. 2006 Jan;51(1):53-9. doi: 10.1016/j.lungcan.2005.07.010. Epub 2005 Sep 16. Lung Cancer. 2006. PMID: 16169121

9

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

Fennell DA, Steele JP, Shamash J, Slater SE, Sheaff MT, Wells P, Rudd RM, Stebbing J. Fennell DA, et al. Int J Cancer. 2007 Dec 1;121(11):2575-7. doi: 10.1002/ijc.22984. Int J Cancer. 2007. PMID: 17680556 Clinical Trial.

10

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. Szlosarek PW, et al. Among authors: rudd rm. Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101. Clin Cancer Res. 2006. PMID: 17145837

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

410 results

Search Page

Filters